Skip to main content
An official website of the United States government

lutetium Lu 177 vipivotide tetraxetan

View Patient Information
A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.
Synonym:177Lu-labeled PSMA-617
177Lu-PSMA-617
Lu177-PSMA-617
lutetium Lu 177-PSMA-617
lutetium-177-PSMA-617
US brand name:Pluvicto
Code name:AAA 617
AAA-617
AAA617
Search NCI's Drug Dictionary